Cellular Therapies and Novel Targeted Agents Will Shape the Future of R/R ALL Management
Marlise Luskin, MD, MSCE, discusses the treatment paradigm for relapsed/refractory ALL and research seeking to integrate agents into the frontline setting
Related Articles
Abenacianine Wins FDA Fast Track Designation for Tumor Visualization in the Lung
Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.
Sasanlimab Plus BCG Could Alter Treatment Paradigm in BCG-Naive, High-Risk NMIBC
Neal Shore, MD, FACS, discusses implications of data for sasanlimab plus BCG in BCG-naive, high-risk non–muscle-invasive bladder cancer.
Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC
Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.
Tisotumab Vedotin Boosts Survival in Chinese Subpopulation With Previously Treated Cervical Cancer
Tisotumab vedotin led to improved survival vs chemotherapy in a Chinese subpopulation of previously treated cervical cancer enrolled in innovaTV 301.
Dr Lee on Real-World Early Outcomes With Second-Line Axi-Cel for R/R LBCL
Dasom (Caroline) Lee, MD, discusses real-world early outcomes of treatment with second-line axi-cel in relapsed/refractory large B-cell lymphoma.
Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC
Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.
PER® Winter Lung Cancer Conference
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Cancer Network
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
ADC Development in Ovarian Cancer: What’s Next for FRa and Beyond?
Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.